Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Breast11
NCT05113251Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2021
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of trastuzumab deruxtecan in breast cancer, sponsored by AstraZeneca. Started Oct 2021; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05113251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113251.